Rina-S
Stories
-
Genmab registers Phase 3 trial of Rina-S in ovarian cancer
The study plans to enroll 602 participants and is expected to start in November 2026. It compares Rina-S alone or in combination with an approved standard of care treatment against the same available standard of care therapy by itself, or no treatment.